TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $94 from $116 and keeps a Hold rating on the shares. The firm said Q4 4 revenues beat, but FY26 revenues guidance down year-over-year as expected due to lower COVID sales, though modest OpEx guide speaks to disciplined spending.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target lowered to $125 from $134 at Morgan Stanley
- BioNTech price target lowered to $128 from $143 at BMO Capital
- BioNTech price target lowered to $130 from $145 at Citi
- Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
- BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks